Axsome Therapeutics, Inc. - Common Stock (AXSM)
CUSIP: 05464T104
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 48,932,355
- Total 13F shares
- 37,843,872
- Share change
- +887,810
- Total reported value
- $3,950,044,159
- Put/Call ratio
- 102%
- Price per share
- $104.39
- Number of holders
- 345
- Value change
- +$74,087,650
- Number of buys
- 204
- Number of sells
- 146
Quarterly Holders Quick Answers
What is CUSIP 05464T104?
CUSIP 05464T104 identifies AXSM - Axsome Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 05464T104:
Top shareholders of AXSM - Axsome Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
7.9%
|
3,876,942
|
$452,167,746 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
7.2%
|
3,524,411
|
$411,052,056 | — | 31 Mar 2025 | |
| RTW INVESTMENTS, LP |
13F
13D/G
|
Company |
3.1%
from 13D/G
|
2,922,729
|
$340,877,883 | — | 31 Mar 2025 | |
| BVF INC/IL |
13F
|
Company |
3.5%
|
1,690,221
|
$197,130,475 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
2.5%
|
1,247,231
|
$145,464,570 | — | 31 Mar 2025 | |
| MACQUARIE GROUP LTD |
13F
|
Company |
2%
|
976,260
|
$113,861,000 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
934,853
|
$109,057,988 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.9%
|
906,020
|
$105,669,113 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
1.8%
|
857,001
|
$99,952,026 | — | 31 Mar 2025 | |
| Fairmount Funds Management LLC |
13F
|
Company |
1.7%
|
815,176
|
$95,073,977 | — | 31 Mar 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
744,850
|
$86,877,079 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.4%
|
703,279
|
$82,023,430 | — | 31 Mar 2025 | |
| ALETHEA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
667,368
|
$77,835,130 | — | 31 Mar 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
1.3%
|
627,418
|
$73,175,761 | — | 31 Mar 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
1.1%
|
556,545
|
$64,909,843 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.1%
|
547,665
|
$63,874,169 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.1%
|
533,902
|
$62,268,990 | — | 31 Mar 2025 | |
| Man Group plc |
13F
|
Company |
1%
|
513,221
|
$59,856,965 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.93%
|
457,416
|
$53,348,530 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.84%
|
413,141
|
$48,184,636 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.84%
|
410,969
|
$47,931,314 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.79%
|
386,700
|
$45,100,821 | — | 31 Mar 2025 | |
| 1832 Asset Management L.P. |
13F
|
Company |
0.74%
|
363,200
|
$42,360,016 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.73%
|
355,107
|
$41,416,129 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.69%
|
337,246
|
$39,333,001 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.68%
|
333,205
|
$38,861,699 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.62%
|
304,084
|
$35,465,317 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.62%
|
301,718
|
$35,189,371 | — | 31 Mar 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.6%
|
295,671
|
$34,484,108 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.59%
|
288,647
|
$33,664,901 | — | 31 Mar 2025 | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. |
13F
|
Company |
0.58%
|
285,494
|
$33,297,165 | — | 31 Mar 2025 | |
| LOOMIS SAYLES & CO L P |
13F
|
Company |
0.58%
|
284,170
|
$33,143,000 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.58%
|
282,376
|
$32,933,513 | — | 31 Mar 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
0.55%
|
266,997
|
$31,140,000 | — | 31 Mar 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.51%
|
250,000
|
$29,157,500 | — | 31 Mar 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.48%
|
235,383
|
$27,452,719 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.48%
|
235,311
|
$27,444,322 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.46%
|
226,515
|
$26,418,446 | — | 31 Mar 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.44%
|
214,139
|
$24,975,032 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.37%
|
182,632
|
$21,300,370 | — | 31 Mar 2025 | |
| MetLife Investment Management, LLC |
13F
|
Company |
0.37%
|
178,955
|
$20,871,522 | — | 31 Mar 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.36%
|
177,814
|
$20,738,478 | — | 31 Mar 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.36%
|
175,942
|
$20,520,115 | — | 31 Mar 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.36%
|
175,317
|
$20,447,222 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.32%
|
155,075
|
$18,086,249 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.31%
|
149,600
|
$17,447,848 | — | 31 Mar 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.29%
|
141,597
|
$16,514,458 | — | 31 Mar 2025 | |
| Granite Investment Partners, LLC |
13F
|
Company |
0.28%
|
138,719
|
$16,178,797 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.27%
|
134,400
|
$15,675,072 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.27%
|
131,023
|
$15,281,205 | — | 31 Mar 2025 |
Institutional Holders of Axsome Therapeutics, Inc. - Common Stock (AXSM) as of Q2 2025
As of 30 Jun 2025,
Axsome Therapeutics, Inc. - Common Stock (AXSM) was held by
345 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,843,872 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., BVF INC/IL, RTW INVESTMENTS, LP, MACQUARIE GROUP LTD, GEODE CAPITAL MANAGEMENT, LLC, FMR LLC, STATE STREET CORP, Fairmount Funds Management LLC, and Deep Track Capital, LP.
This page lists
346
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
349
Q2 2025 holders
345
Holder diff
-4
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.